Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

ELAINE Trial Explores Lasofoxifene in ESR1+ Breast Cancer

Ellie Leick
Published: Wednesday, Dec 18, 2019

Matthew P. Goetz, MD, a professor of oncology and pharmacology and consultant in the Department of Oncology at Mayo Clinic

Matthew P. Goetz, MD

Patients with estrogen receptor (ER)–positive, HER2-negative breast cancer can develop resistance to tamoxifen and aromatase inhibitors with the emergence of ESR1 mutations, leaving oncologists questioning the next steps in treatment for this patient population, explained Matthew P. Goetz, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication